Advertisement

Topics

Chemconserve Development Company B.V. Company Profile

14:08 EST 9th December 2018 | BioPortfolio

We are always interested to learn about waste streams containing a valuable chemical. We study whether it is possible to market the byproduct stream as such, or whether the valuable compound(s) could be isolated and marketed.

There are some criteria:

a steady stream from a process that has already run for some years (i.e. has been optimized) and that will continue for the foreseeable future.
a significant amount of product in the stream, not 100 compounds in low percentages.
complete analysis available.
Using our brains and our connections, we will establish if the product would be marketable and devise a way of extracting and purifying it. Such an operation could then be performed on site by the generator of the waste stream, or elsewhere by a toll-converter. We are interested to market the product if it cannot be returned to its source.

Location

Zurich TowerMuzenstraat 89
The Hague
2511 WB
Netherlands

Contact

Phone: 31 (0) 70 4262170
Fax: 31 (0) 70 4262404
Email: chem@chemconserve.com


News Articles [174 Associated News Articles listed on BioPortfolio]

Puerto Rico Industrial Development Company: Much more than just tax breaks

In this episode of PharmaTelevision News Review, filmed at #BIO2012 Convention in Boston, Fintan Walton talks to Victor Merced, Life Sciences Director at Puerto Rico Industrial Development Company

Hemostemix Announces Development of an ACP-01 Allogeneic Process and Initiation of R&D for Autologous NCP-01

Hemostemix (TSXV:HEM; OTCQB:HMTXF) is pleased to provide the following update on its research and development activities. As quoted in the press release: Further to the Company’s press release date...

Relay Medical Introduces the Pharmatrac Technology and Reports on Development

Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) ("Relay" or the "Company"), an engine of MedTech innovation, is pleased to introduce the Company's Pharmatrac Technology and report on relate...

Sosei, Allergan voluntarily suspend clinical development of HTL0018318

Sosei Group Corporation, the world leader in GPCR medicine design and development, announces that the Company and Allergan, its license partner for HTL0018318, have decided to voluntarily suspend clin...

Organovo Reports Fiscal First-Quarter 2019 Results; Company Outlines and Expands Key Clinical Development Goals

Organovo (NASDAQ:ONVO) a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today reported its fiscal fi...

Eli Lilly's Positive Diabetes Trial Results Inspire Confidence as Company Prepares for Phase 3 Studies

NewsEli Lilly and Company has successful engineered a single molecule that acts on two receptors in the body: GIP and GLP.

4D pharma talks about development of live biotherapeutics at IHMC 2018

4D pharma plc, a pharmaceutical company leading the development of live biotherapeutics, announced that the Company's Chief Scientific Officer, Dr. Alex Stevenson, has spoken at the International Hum...

PreveCeutical Announces First Cannabis Product for Treatment of Anxiety

PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H) (the "Company" or "PreveCeutical"), announces the first product development program of the Company's newly created medicinal cannabis di...

PubMed Articles [754 Associated PubMed Articles listed on BioPortfolio]

Characteristics of Occupational Injuries in a Pharmaceutical Company in Iran.

To prioritize occupational hazards in a Pharmaceutical Company in Iran using the analytical hierarchy process (AHP).

A Man (or a Woman) is Known by the Company He/She Keeps.

Epidemiologic challenges in norovirus vaccine development.

Norovirus is the leading cause of acute gastroenteritis (AGE) worldwide. In the United States norovirus is estimated to cause 19-21 million illnesses, 1.7-1.9 million outpatient visits, 56,000-71,00...

Notes from the Field: Lead Exposures Among Employees at a Bullet Manufacturing Company - Missouri, 2017.

Significant Decreasing Trend in Low Back Injuries in a Beverage Company.

Work-related injuries in the U.S. have steadily declined over the past three decades.

Clinical Trials [1858 Associated Clinical Trials listed on BioPortfolio]

Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago

To continue the comprehensive research program on the epidemiology of cardiovascular and other major chronic diseases, including cancer and diabetes, in four Chicago population cohorts. T...

Immunogenicity and Safety of Kinrix + MMR With and Without Varicella Vaccine in Healthy Children 4-6 Years

The purpose of the study is to evaluate the immunogenicity and safety of Kinrix when co-administered with varicella (Varivax® [varicella virus vaccine live], Merck and Company) and MMR va...

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects

- Objective: - A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Co...

Effects of Insufflated Gas on Core Temperature and Post-operative Pain During Laparoscopic Surgery

During laparoscopy, administration of cold and dry carbon dioxide (CO2) leads to hypothermia. Different types of gas conditioning have been studied in order to prevent this specific hypoth...

Bioequivalence Study of Cefprozil Tablets, USP 500 mg Undef Fed Conditions

The objective of this study is to assess the single - dose relative bioavailability of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fed conditions.

Companies [2801 Associated Companies listed on BioPortfolio]

Chemconserve Development Company B.V.

We are always interested to learn about waste streams containing a valuable chemical. We study whether it is possible to market the byproduct stream as such, or whether the valuable compound(s) could ...

Millennium: The Takeda Oncology Company

Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets a first-in-class proteasome inhibitor, and has a robust clinical de...

Liposome Company Incorporated

The Liposome Company Incorporated. is a biopharmaceutical company engaged in the discovery, development, manufacturing and marketing of proprietary lipid- and liposome-based pharmaceuticals, p...

Tridelta plc

Tridelta plc is the Parent Company of Tridelta Development Limited, which specialises in the Research, Development, Manufacturing and Marketing of Diagnostic Products for application principally withi...

KOS Pharmaceuticals Incorporated

Kos Pharmaceuticals, Inc. is a fully-integrated specialty pharmaceutical company engaged in the development of proprietary prescription products for the treatment of certain chronic cardiovascular and...

More Information about "Chemconserve Development Company B.V." on BioPortfolio

We have published hundreds of Chemconserve Development Company B.V. news stories on BioPortfolio along with dozens of Chemconserve Development Company B.V. Clinical Trials and PubMed Articles about Chemconserve Development Company B.V. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chemconserve Development Company B.V. Companies in our database. You can also find out about relevant Chemconserve Development Company B.V. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record